| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Cameron JS | |
| P433 | issue | 2 | |
| P304 | page(s) | 413-424 | |
| P577 | publication date | 1999-02-01 | |
| P1433 | published in | Journal of the American Society of Nephrology | Q17123893 |
| P1476 | title | Lupus nephritis | |
| P478 | volume | 10 |
| Q33868909 | A clinico-pathological study of lupus nephritis based on the International Society of Nephrology-Renal Pathology Society 2003 classification system |
| Q40563490 | ANCA-associated Goodpasture's syndrome in a patient with rheumatoid arthritis on penicillamine |
| Q81796951 | Alteration of N-glycosylation in the kidney in a mouse model of systemic lupus erythematosus: relative quantification of N-glycans using an isotope-tagging method |
| Q38777004 | An unusual case of crescentic lupus nephritis presenting with normal renal function |
| Q54214340 | Annexin A1 and Autoimmunity: From Basic Science to Clinical Applications. |
| Q35448756 | Anti-C1q antibodies as a follow-up marker in SLE patients |
| Q37486571 | Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. |
| Q79369720 | Anti-C1q autoantibodies in murine lupus nephritis |
| Q34457056 | Anti-dsDNA antibodies bind to mesangial annexin II in lupus nephritis |
| Q42653229 | Antibiotics ameliorate lupus-like symptoms in mice. |
| Q36076063 | Association of intrarenal B-cell infiltrates with clinical outcome in lupus nephritis: a study of 192 cases |
| Q38023852 | Autoantibodies and resident renal cells in the pathogenesis of lupus nephritis: getting to know the unknown. |
| Q34409787 | Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial |
| Q37058781 | Biomarkers in systemic lupus erythematosus: challenges and prospects for the future |
| Q39534956 | Blunting Autoantigen-induced FOXO3a Protein Phosphorylation and Degradation Is a Novel Pathway of Glucocorticoids for the Treatment of Systemic Lupus Erythematosus |
| Q47952057 | Bone Disease in Connective Tissue Disease/Systemic Lupus Erythematosus. |
| Q51016561 | CCR5Δ32 (rs333) polymorphism is associated with the susceptibility to systemic lupus erythematosus in female Brazilian patients. |
| Q36166909 | CD47 deficiency ameliorates autoimmune nephritis in Fas(lpr) mice by suppressing IgG autoantibody production |
| Q49349531 | Causes and predictors of mortality in biopsy-proven lupus nephritis: the Sarawak experience |
| Q83730088 | Characteristics and influence factors of pathologic transformation in the subclasses of class IV lupus nephritis |
| Q36663933 | Characterization of Patients With Lupus Nephritis Included in a Large Cohort From the Spanish Society of Rheumatology Registry of Patients With Systemic Lupus Erythematosus (RELESSER). |
| Q39067278 | Childhood versus adult-onset systemic lupus erythematosus: long-term outcome and predictors of mortality. |
| Q90092421 | Chinese patent medicine Bailing capsule for treating lupus nephritis: A protocol for systematic review and meta-analysis |
| Q58801489 | Circulating Angiogenic T Cells Are Increased in Lupus Nephritis Patients |
| Q42019937 | Clinical features and mortality in Chinese with lupus nephritis and neuropsychiatric lupus: A 124-patient study |
| Q36752458 | Clinical features, epidemiology, and short-term outcomes of proliferative lupus nephritis in Eastern India |
| Q51775346 | Clinical outcomes of childhood lupus nephritis: a single center's experience. |
| Q36902869 | Clinical outcomes of kidney transplants on patients with end-stage renal disease secondary to lupus nephritis, polycystic kidney disease and diabetic nephropathy |
| Q36246049 | Clinicopathologic correlations of renal microthrombosis and inflammatory markers in proliferative lupus nephritis |
| Q33991334 | Clinicopathological correlations in lupus nephritis; a single center experience |
| Q51776721 | Clinicopathological correlations of paediatric lupus nephritis. |
| Q36266807 | Clinicopathological findings, treatment response and predictors of long-term outcome in a cohort of lupus nephritis patients managed according to the Euro-lupus regime: a retrospective analysis in Sri Lanka |
| Q47211298 | Clinicopathological study of male and female patients with lupus nephritis: a retrospective study |
| Q44800170 | Clinicopathological study of the WHO classification in childhood lupus nephritis |
| Q34309764 | Combination treatment in autoimmune diseases: systemic lupus erythematosus. |
| Q94521105 | Comprehensive aptamer-based screening identifies a spectrum of urinary biomarkers of lupus nephritis across ethnicities |
| Q90113235 | Curcumin Attenuates Both Acute and Chronic Immune Nephritis |
| Q38855495 | Current and Emerging Therapies for Lupus Nephritis |
| Q33882751 | Current status of lupus nephritis |
| Q35838299 | Cyclophosphamide treatment in systemic necrotizing vasculitis and lupus nephritis. How long? How much? |
| Q56891036 | Defective BTLA functionality is rescued by restoring lipid metabolism in lupus CD4+ T cells |
| Q46810854 | Defining the role of mycophenolate mofetil in the treatment of proliferative lupus nephritis. |
| Q55027053 | Dysregulated heme oxygenase-1low M2-like macrophages augment lupus nephritis via Bach1 induced by type I interferons. |
| Q35051164 | ESRD from lupus nephritis in the United States, 1995-2010 |
| Q38028010 | Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials |
| Q34490782 | Efficacy of long-term maintenance therapy with mycophenolate mofetil in lupus nephritis |
| Q53311588 | Enteric-coated mycophenolate sodium in pediatric lupus nephritis: a retrospective cohort study. |
| Q33366672 | Epidemiology treatment and outcome of childhood systemic lupus erythematosus in Egypt |
| Q64263389 | Epoxyeicosatrienoic Acid Analog EET-A Blunts Development of Lupus Nephritis in Mice |
| Q26782273 | Extracellular Vesicles as Biomarkers of Systemic Lupus Erythematosus |
| Q37341083 | Features and outcomes of lupus nephritis in Morocco: analysis of 114 patients |
| Q90087876 | Focal proliferative and necrotizing glomerulonephritis presenting with mild urinary abnormalities and normal renal function in a young adult |
| Q30456024 | Genetic approach to study lupus glomerulonephritis |
| Q35422370 | Glomerular Autoimmune Multicomponents of Human Lupus Nephritis In Vivo (2): Planted Antigens. |
| Q30596600 | Glomerular autoimmune multicomponents of human lupus nephritis in vivo: α-enolase and annexin AI. |
| Q41670053 | HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus |
| Q41861387 | Hidden face of lupus nephritis exposed: Isolated tubulointerstitial lupus nephritis |
| Q89919108 | Hypokalaemia in Sjögren's syndrome: the missing piece |
| Q50958361 | IL-3 contributes to development of lupus nephritis in MRL/lpr mice. |
| Q41940915 | ISN/RPS 2003 classification of lupus nephritis: time to take a look on the achievements and limitations of the schema. |
| Q64994682 | Immunoglobulin Binding Protein 1 as a Potential Urine Biomarker in Patients with Lupus Nephritis. |
| Q35552600 | Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment |
| Q56888698 | Inter-molecular epitope spreading does not lead to extension of autoimmunity beyond target tissue in autoimmune glomerulonephritis |
| Q44894708 | Intravenous cyclophosphamide--resistant systemic lupus erythematosus in Arizona |
| Q35746436 | Juvenile systemic lupus erythematosus: A diagnostic dilemma |
| Q41014332 | Kidney Expression of Toll Like Receptors in Lupus Nephritis: Quantification and Clinicopathological Correlations. |
| Q39789199 | Long-term Outcome of Lupus Nephritis Class II in Argentine Patients: An Open Retrospective Analysis |
| Q55078673 | Lupus nephritis in Bangladesh: unfolding the story. |
| Q35591764 | Lupus nephritis in childhood: a review of 53 patients followed at a single center |
| Q38608138 | Lupus nephritis: an update |
| Q22000837 | Lupus nephritis: current update |
| Q38162780 | Lupus nephritis: review of the literature |
| Q37221965 | Mediators of inflammation and their effect on resident renal cells: implications in lupus nephritis |
| Q30429535 | Mesangial pathology in glomerular disease: targets for therapeutic intervention |
| Q35756700 | Methylprednisolone attenuates lipopolysaccharide-induced Fractalkine expression in kidney of Lupus-prone MRL/lpr mice through the NF-kappaB pathway |
| Q90291308 | Microarray expression and functional analysis of circular RNAs in the glomeruli of NZB/W F1 mice with lupus nephritis |
| Q58698442 | Microthrombotic Renal Vascular Lesions Are Associated to Increased Renal Inflammatory Infiltration in Murine Lupus Nephritis |
| Q37709460 | Monoclonal Antibodies for Systemic Lupus Erythematosus (SLE). |
| Q37290624 | Mycophenolate mofetil in the treatment of lupus nephritis. |
| Q64261947 | Mycophenolate mofetil reduces STAT3 phosphorylation in systemic lupus erythematosus patients |
| Q40507229 | NMR based serum metabolomics reveals a distinctive signature in patients with Lupus Nephritis |
| Q92051265 | Neutrophil Extracellular Traps Profiles in Patients with Incident Systemic Lupus Erythematosus and Lupus Nephritis |
| Q26796871 | Non-invasive imaging to monitor lupus nephritis and neuropsychiatric systemic lupus erythematosus |
| Q28384306 | Nrf2 suppresses lupus nephritis through inhibition of oxidative injury and the NF-κB-mediated inflammatory response |
| Q37006437 | Nuclear factor erythroid 2-related factor 2 is a critical target for the treatment of glucocorticoid-resistant lupus nephritis |
| Q30409205 | P2X7 blockade attenuates murine lupus nephritis by inhibiting activation of the NLRP3/ASC/caspase 1 pathway |
| Q50616527 | Persistent hypertension in lupus nephritis and the associated risk factors. |
| Q84145951 | Predictive value of remission status after 6 months induction therapy in patients with proliferative lupus nephritis: a retrospective analysis |
| Q36259961 | Prolactin and Dehydroepiandrosterone Levels in Women with Systemic Lupus Erythematosus: The Role of the Extrapituitary Prolactin Promoter Polymorphism at -1149G/T |
| Q79717881 | Pulmonary thrombosis as the first manifestation of systemic lupus erythematosus in a 14-year-old boy |
| Q36697845 | Renal Biopsy: A much needed tool in patients with Systemic Lupus Erythematosis (SLE). |
| Q36186103 | Reno-protective effect and mechanism study of Huang Lian Jie Du Decoction on lupus nephritis MRL/lpr mice |
| Q36472640 | Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA. |
| Q35858533 | Retrospective study of plasma exchange in children with systemic lupus erythematosus |
| Q33497970 | Risk factors and impact of recurrent lupus nephritis in patients with systemic lupus erythematosus undergoing renal transplantation: data from a single US institution |
| Q30576975 | Risk factors for renal failure in patients with lupus nephritis: data from the spanish registry of glomerulonephritis |
| Q33885872 | Rituximab alone as induction therapy for membranous lupus nephritis: A multicenter retrospective study. |
| Q35899141 | Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis |
| Q38021183 | Role of TWEAK in lupus nephritis: a bench-to-bedside review |
| Q41230561 | Serum levels of adiponectin and leptin as biomarkers of proteinuria in lupus nephritis |
| Q42281246 | Serum protein pattern associated with organ damage and lupus nephritis in systemic lupus erythematosus revealed by PEA immunoassay |
| Q50946034 | Serum uric acid levels contribute to new renal damage in systemic lupus erythematosus patients. |
| Q87705292 | Short-interval lower-dose intravenous cyclophosphamide as induction and maintenance therapy for lupus nephritis: a prospective observational study |
| Q41885272 | Sjögren Syndrome-Related Membranous Glomerulonephritis Progressing to Membranoproliferative Glomerulonephritis |
| Q49486030 | Systematic evaluation of different doses of cyclophosphamide induction therapy for lupus nephritis |
| Q94481959 | Systematic review and meta-analysis of clinical outcomes comparison between different initial dialysis modalities in end-stage renal disease patients due to lupus nephritis prior to renal transplantation |
| Q21195423 | Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis |
| Q36246074 | Systemic lupus erythematosus and fractures. |
| Q37857386 | Systemic lupus erythematosus associated with type 4 renal tubular acidosis: a case report and review of the literature |
| Q58779764 | Systemic lupus erythematosus of the urinary tract: focus on lupus cystitis |
| Q51345238 | Targeting the B-cell pathway in lupus nephritis: current evidence and future perspectives. |
| Q36960116 | The Characteristics and Significance of Locally Infiltrating B Cells in Lupus Nephritis and Their Association with Local BAFF Expression |
| Q42234669 | The Friend leukaemia virus integration 1 (Fli-1) transcription factor affects lupus nephritis development by regulating inflammatory cell infiltration into the kidney |
| Q84974441 | The Persistent Challenge of Lupus Nephritis |
| Q42043384 | The Role of Hyaluronan and CD44 in the Pathogenesis of Lupus Nephritis. |
| Q28585701 | The peroxisome proliferator-activated receptor gamma agonist rosiglitazone ameliorates murine lupus by induction of adiponectin |
| Q33349226 | The renal metallothionein expression profile is altered in human lupus nephritis |
| Q37308042 | The search for lupus biomarkers |
| Q33405303 | The spectrum of renal thrombotic microangiopathy in lupus nephritis |
| Q53533440 | Thrombotic thrombocytopenic purpura in a new onset lupus patient? |
| Q36368688 | Treatment for lupus nephritis: an overview of systematic reviews and meta-analyses |
| Q37822658 | Treatment of proliferative lupus nephritis: a slowly changing landscape |
| Q35201234 | Treatment of severe proliferative lupus nephritis: the current state |
| Q37288728 | Treatment options for proliferative lupus nephritis: an update of clinical trial evidence |
| Q35019423 | Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. |
| Q36832462 | Urinary angiostatin--a novel putative marker of renal pathology chronicity in lupus nephritis |
| Q34050022 | Urinary biomarkers in lupus nephritis |
| Q36713542 | Urinary vascular cell adhesion molecule, but not neutrophil gelatinase-associated lipocalin, is associated with lupus nephritis |
| Q36633311 | Urine VCAM-1 as a marker of renal pathology activity index in lupus nephritis |
| Q34082546 | Urine proteome scans uncover total urinary protease, prostaglandin D synthase, serum amyloid P, and superoxide dismutase as potential markers of lupus nephritis. |
| Q36203113 | Utility of untimed single urine protein/creatinine ratio as a substitute for 24-h proteinuria for assessment of proteinuria in systemic lupus erythematosus. |
| Q84378946 | [Renal emergencies in cases of collagenosis and vasculitis] |
| Q81499380 | [Renal manifestations of rheumatic diseases] |
| Q28083028 | miRNAs in the Pathogenesis of Systemic Lupus Erythematosus |
Search more.